A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

NCT01358734 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Myelogenous Leukemia

Interventions

DRUG: Azacitidine
DRUG: Lenalidomide
OTHER: Best Supportive Care (BSC)

Sponsor

Celgene